BEVYXXA
Total Payments
$4.0M
Transactions
8,418
Doctors
4,420
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $47,411 | 1 | 0 |
| 2019 | $17,054 | 79 | 64 |
| 2018 | $4.0M | 8,338 | 4,366 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 521 | 42.1% |
| Unspecified | $1.4M | 9 | 34.9% |
| Consulting Fee | $384,621 | 8 | 9.5% |
| Food and Beverage | $283,320 | 7,106 | 7.0% |
| Travel and Lodging | $204,671 | 688 | 5.1% |
| Space rental or facility fees (teaching hospital only) | $42,950 | 21 | 1.1% |
| Honoraria | $12,000 | 6 | 0.3% |
| Education | $1,996 | 59 | 0.0% |
Payments by Type
General
$2.6M
8,409 transactions
Research
$1.4M
9 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| APEX TRIAL: EXECUTIVE COMMITTEE AGREEMENT | PORTOLA PHARMACEUTICALS, INC. | $562,500 | 0 |
| 17-022 | PORTOLA PHARMACEUTICALS, INC. | $549,459 | 0 |
| DCRI #7488 BRAVO (BETRIXABAN) REGISTRY | Portola Pharmaceuticals, Inc. | $250,000 | 0 |
Top Doctors Receiving Payments for BEVYXXA — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Mc Minnville, TN | $6,210 | 9 |
| , MD | Critical Care Medicine | Los Angeles, CA | $6,172 | 21 |
| , MD | Clinical Cardiac Electrophysiology | Pensacola, FL | $5,949 | 9 |
| , M.D | Internal Medicine | Pascagoula, MS | $5,889 | 12 |
| , MD | Cardiovascular Disease | Memphis, TN | $5,874 | 16 |
| , MD | Interventional Cardiology | Birmingham, AL | $5,783 | 10 |
| , MD | Internal Medicine | Stockton, CA | $5,733 | 13 |
| , MD | Neurology | Greensboro, NC | $5,680 | 6 |
| , M.D | Pulmonary Disease | Hauppauge, NY | $5,628 | 9 |
| , M.D | Hematology & Oncology | Miami, FL | $5,515 | 7 |
| , M.D | Cardiovascular Disease | Miami, FL | $5,302 | 11 |
| , DO | Hematology & Oncology | West Reading, PA | $5,021 | 10 |
| , M.D | Pulmonary Disease | Phoenix, AZ | $4,349 | 7 |
| , MD | Emergency Medicine | Morristown, NJ | $4,263 | 5 |
| , MD | Internal Medicine | Alhambra, CA | $4,123 | 6 |
| , MD | Hospitalist | Lehi, UT | $4,107 | 7 |
| , M.D | Internal Medicine | Boston, MA | $4,076 | 3 |
| , MD | Allergy & Immunology | Los Angeles, CA | $3,865 | 6 |
| , MD | Internal Medicine | Newark, NJ | $3,804 | 6 |
| , MD | Nephrology | Orlando, FL | $3,706 | 8 |
| , MD | Surgery | Philadelphia, PA | $3,674 | 3 |
| , D.O | Addiction Medicine | Albuquerque, NM | $3,591 | 7 |
| , M.D | Hospitalist | Mattoon, IL | $3,520 | 8 |
| Mark Rumbak | — | Tampa, FL | $3,366 | 4 |
| , M.D | Cardiovascular Disease | Torrance, CA | $3,303 | 6 |
Ad
Manufacturing Companies
- PORTOLA PHARMACEUTICALS, INC. $3.7M
- Portola Pharmaceuticals, Inc. $250,007
- PORTOLA PHARMACEUTICALS, LLC $47,411
Product Information
- Type Drug
- Total Payments $4.0M
- Total Doctors 4,420
- Transactions 8,418
About BEVYXXA
BEVYXXA is a drug associated with $4.0M in payments to 4,420 healthcare providers, recorded across 8,418 transactions in the CMS Open Payments database. The primary manufacturer is PORTOLA PHARMACEUTICALS, INC..
Payment data is available from 2018 to 2020. In 2020, $47,411 was paid across 1 transactions to 0 doctors.
The most common payment nature for BEVYXXA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.7M, 42.1% of total).
BEVYXXA is associated with 3 research studies, including "APEX TRIAL: EXECUTIVE COMMITTEE AGREEMENT" ($562,500).